title: CD98hc (SLC3A2), a novel marker in renal cell cancer.
abstract: BACKGROUND
  In a variety of malignant diseases, molecular targeting represents a therapeutic option, whereby, when compared with chemotherapy, fewer side effects are thought to be expected. Especially in renal cell cancer (RCC), tyrosine kinase-inhibitors have been established as useful and highly effective therapy. However, tyrosine kinase-inhibitors currently approved for RCC treatment lack single molecule specificity and bear a variety of side effects of the gastro-intestinal tract, skin, heart and haematopoietic system. Therefore, the identification of novel cell surface markers is sought, which might lead to novel diagnostic and therapeutic strategies in cancer.
  
  
  METHODS
  Paraffin-embedded RCCs from a well characterized tissue bank were immunohistochemically quantified for embryonic transmembrane antigen CD98hc (SLC3A2) expression and semi-quantitative analyses were correlated with subtype or grade of differentiation.
  
  
  RESULTS
  We found increased CD98hc expression in different types of malign RCCs, among them clear cell (cc)RCC, papillary (p)RCC and chromophobe (ch)RCC, but lack of expression in the benign renal oncocytoma. Thereby, the extent of CD98hc expression directly complies with grade of malignancy. Furthermore, the more malignant type II pRCC significantly higher expressed CD98hc than the less malignant and more differentiated type I pRCC (type II 83.34%, type I 4.76% CD98hc positive, P < 0.00001; n = 51). The established marker for type I pRCC, Cytokreatin 7, showed 95.24% expression in type I and 26.67% expression in type II pRCC (P < 0.00001, n = 51).
  
  
  CONCLUSIONS
  From these data, we conclude that CD98hc is expressed in RCCs, whereby the extent of expression is likely to correlate directly with grade of malignancy. In pRCCs, CD98hc might represent a novel and reliable marker for type II pRCC.
authors.affiliation: Department of Medicine I, Medical University of Vienna, Vienna, Austria. gerald.prager@medunwien.ac.at
authors.forename: G W
authors.initials: GW
authors.lastname: Prager
authors.forename: M
authors.initials: M
authors.lastname: Poettler
authors.forename: M
authors.initials: M
authors.lastname: Schmidinger
authors.forename: P R
authors.initials: PR
authors.lastname: Mazal
authors.forename: M
authors.initials: M
authors.lastname: Susani
authors.forename: C C
authors.initials: CC
authors.lastname: Zielinski
authors.forename: A
authors.initials: A
authors.lastname: Haitel
mesh_terms: D014408:Biomarkers, Tumor / Q000378:metabolism*; D015153:Blotting, Western; D002292:Carcinoma, Renal Cell / Q000175:diagnosis*; D005434:Flow Cytometry; D027282:Fusion Regulatory Protein 1, Heavy Chain / Q000378:metabolism*; D006801:Humans; D007680:Kidney Neoplasms / Q000175:diagnosis*; D013223:Statistics as Topic
chemical_list: D014408:Biomarkers, Tumor; D027282:Fusion Regulatory Protein 1, Heavy Chain